No, we haven't said we're against a universal pharmacare program. All we're saying is, to date, that has been the one model that has dominated the discussion, and some of the economic modelling around that has turned out to be inaccurate.
Our most recent study showed that it would actually lead to a transfer of costs from the private sector to the public sector of an additional $6.6 billion. We're not against it. It has its merits. What we're suggesting is this is Canadians' hard-earned taxpayer money and we want to make sure that governments invest it wisely. We're about to come out with some research on different models of pharmacare, because pharmacare means different things to different people. Moving forward, we want to make sure that government is making an informed decision about the right implementation path.